These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37688574)

  • 21. CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.
    Van Bergen NJ; Massey S; Quigley A; Rollo B; Harris AR; Kapsa RMI; Christodoulou J
    Biochem Soc Trans; 2022 Aug; 50(4):1207-1224. PubMed ID: 35997111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    Tang S; Terzic B; Wang IJ; Sarmiento N; Sizov K; Cui Y; Takano H; Marsh ED; Zhou Z; Coulter DA
    Nat Commun; 2019 Jun; 10(1):2655. PubMed ID: 31201320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
    Kilstrup-Nielsen C; Rusconi L; La Montanara P; Ciceri D; Bergo A; Bedogni F; Landsberger N
    Neural Plast; 2012; 2012():728267. PubMed ID: 22779007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
    Sampedro-Castañeda M; Baltussen LL; Lopes AT; Qiu Y; Sirvio L; Mihaylov SR; Claxton S; Richardson JC; Lignani G; Ultanir SK
    Nat Commun; 2023 Dec; 14(1):7830. PubMed ID: 38081835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder.
    Tassinari M; Mottolese N; Galvani G; Ferrara D; Gennaccaro L; Loi M; Medici G; Candini G; Rimondini R; Ciani E; Trazzi S
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.
    Vigli D; Rusconi L; Valenti D; La Montanara P; Cosentino L; Lacivita E; Leopoldo M; Amendola E; Gross C; Landsberger N; Laviola G; Kilstrup-Nielsen C; Vacca RA; De Filippis B
    Neuropharmacology; 2019 Jan; 144():104-114. PubMed ID: 30326240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
    Jhang CL; Lee HY; Chen JC; Liao W
    Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain.
    Silvestre M; Dempster K; Mihaylov SR; Claxton S; Ultanir SK
    Mol Psychiatry; 2024 Jun; 29(6):1844-1856. PubMed ID: 38326557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDKL5 deficiency causes epileptic seizures independent of cellular mosaicism.
    Takahashi S; Takeguchi R; Tanaka R; Fukuoka M; Koike T; Ohtani H; Inoue K; Fukuda M; Kurahashi H; Nakamura K; Tominaga K; Matsubayashi T; Itoh M; Tanaka T
    J Neurol Sci; 2022 Dec; 443():120498. PubMed ID: 36417806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
    Fuchs C; Gennaccaro L; Trazzi S; Bastianini S; Bettini S; Lo Martire V; Ren E; Medici G; Zoccoli G; Rimondini R; Ciani E
    Neural Plast; 2018; 2018():9726950. PubMed ID: 29977282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKL5 Deficiency Disorder Without Epilepsy.
    Aznar-Laín G; Fernández-Mayoralas DM; Caicoya AG; Rocamora R; Pérez-Jurado LA
    Pediatr Neurol; 2023 Jul; 144():84-89. PubMed ID: 37201242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder.
    Fuchs C; Cosentino L; Urbinati C; Talamo MC; Medici G; Quattrini MC; Mottolese N; Pietraforte D; Fuso A; Ciani E; De Filippis B
    CNS Neurosci Ther; 2022 Nov; 28(11):1718-1732. PubMed ID: 35932179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.
    Trazzi S; De Franceschi M; Fuchs C; Bastianini S; Viggiano R; Lupori L; Mazziotti R; Medici G; Lo Martire V; Ren E; Rimondini R; Zoccoli G; Bartesaghi R; Pizzorusso T; Ciani E
    Hum Mol Genet; 2018 May; 27(9):1572-1592. PubMed ID: 29474534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
    Carli S; Chaabane L; Butti C; De Palma C; Aimar P; Salio C; Vignoli A; Giustetto M; Landsberger N; Frasca A
    J Neurochem; 2021 May; 157(4):1253-1269. PubMed ID: 33448385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow blockage disrupts cilia-driven fluid transport in the epileptic brain.
    Faubel RJ; Santos Canellas VS; Gaesser J; Beluk NH; Feinstein TN; Wang Y; Yankova M; Karunakaran KB; King SM; Ganapathiraju MK; Lo CW
    Acta Neuropathol; 2022 Oct; 144(4):691-706. PubMed ID: 35980457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel CDKL5 targets identified in human iPSC-derived neurons.
    Massey S; Ang CS; Davidson NM; Quigley A; Rollo B; Harris AR; Kapsa RMI; Christodoulou J; Van Bergen NJ
    Cell Mol Life Sci; 2024 Aug; 81(1):347. PubMed ID: 39136782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKL5-associated developmental and epileptic encephalopathy: A long-term, longitudinal electroclinical study of 22 cases.
    Darra F; Monchelato M; Loos M; Juanes M; Bernardina BD; Valenzuela GR; Gallo A; Caraballo R
    Epilepsy Res; 2023 Feb; 190():107098. PubMed ID: 36739728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.
    Yan Y; He D; Wu J; Hou R; Sun K; Li L
    Ital J Pediatr; 2020 Feb; 46(1):27. PubMed ID: 32111237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral impulsivity is associated with pupillary alterations and hyperactivity in CDKL5 mutant mice.
    Viglione A; Sagona G; Carrara F; Amato G; Totaro V; Lupori L; Putignano E; Pizzorusso T; Mazziotti R
    Hum Mol Genet; 2022 Nov; 31(23):4107-4120. PubMed ID: 35861639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKL5 sculpts functional callosal connectivity to promote cognitive flexibility.
    Awad PN; Zerbi V; Johnson-Venkatesh EM; Damiani F; Pagani M; Markicevic M; Nickles S; Gozzi A; Umemori H; Fagiolini M
    Mol Psychiatry; 2024 Jun; 29(6):1698-1709. PubMed ID: 36737483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.